Keros Therapeutics, Inc. booked $244.1M in FY2025 revenue, growing 6775% year over year — faster than 99% of Healthcare companies we track, at a 35.7% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.